No. 2 East Fuxing Road
About Fosun Pharma
100 articles with Fosun Pharma
March 22, 2022, Shanghai Fosun Pharmaceutical Co., Ltd., a global innovation-driven pharmaceutical and healthcare industry group in China, announced its annual results for the year of 2021, together with its 2021 Corporate Social Responsibility report.
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its interim results for the first half of 2021 ("the Reporting Period").
Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment
Polyphor AG announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China.
Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone
The Net Profit Attributable to Shareholders Increased 13.1% as Compared to the Same Period in 2019 with Innovation Transformation and Integrated Operation Actively Promoted [26-August-2020] SHANGHAI , Aug. 26, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) , a leading healthcare group in Chin
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
Phase 1 study will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval pathway in China
Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) announces that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharmaceutical Industrial") has received the acceptance notice of clinical trial application for the licensed COVID-19 vaccine product candid
Fosun Pharma Invites Chinese and Foreign Experts to Jointly Discuss Prevention and Control Measures of COVID-19 Epidemic in Africa
In order to support African medical institutions in their response to the COVID-19 pandemic, Fosun Pharma, partnering with Shanghai Fosun Foundation, Fosun Medical and Tridem Pharma, People's Daily Health platform and the Health Times, held an "eCME on COVID-19 Case Management" at 19:00 Beijing time, 28 April.
SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration, Shanghai Fosun Pharmaceutical Co., Ltd has received emergency use authorization from FDA for its COVID-19 RT-PCR detection kit.
Revenues and Net Profits Maintain Solid Growth with Remarkable Globalization Innovation Capability
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
BioNTech and Fosun Pharma will jointly conduct clinical trials of BNT162 in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and commercialization capabilities in China
MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China
Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy
ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales
The completion of this investment was notably subject to the obtention of Chinese regulatory authorizations and to the visa of the French financial markets authority on the prospectus related to the Share Capital Increase.
EOS Imaging, the pioneer of orthopedic medical imaging 2D / 3D, today announced that it entered into a binding agreement with Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical Co., Ltd., related to an equity investment to be made by Fosun Pharmaceutical AG through an issuance of EOS imaging news shares.
Shanghai Fosun Pharma announced a $50M U.S. joint venture, a JV that includes two Fosun entities.
Fosun Pharma acquired China rights to market a novel treatment for Parkinson's disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.